Vistagen Q1 FY2025 net loss $10.7M; PALISADE Phase 3 trials on track for 2025 results

Vistagen Therapeutics, Inc.

2025-Q1 EPS reported -$0.35 vs consensus -$0.51 ▲ beat (+30.9%)

Net loss of $10.7M for Q1 FY2025, up from $6.9M in Q1 FY2024.
Cash, cash equivalents, and marketable securities at $108.4M as of June 30, 2024.
PALISADE-3 Phase 3 trial for fasedienol in SAD on track for top-line results in 2025.
PALISADE-4 Phase 3 trial preparation ongoing; initiation planned H2 2024.
R&D expenses increased to $7.6M from $4.2M due to PALISADE trial costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.